All In Biotech

Drug Trial Radar · NCT00003728

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood

Last checked: Nov 20, 2026Latest source record: Jan 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,500

Planned (sponsor's estimate)

Start

Dec 1998

Primary completion

May 2008

Sponsor

Sponsor type
Research network
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy plus steroid therapy is more effective for acute lymphoblastic leukemia or lymphoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy plus steroid therapy in treating children who have acute lymphoblastic leukemia or lymphoblastic non-Hodgkin's lymphoma.

Conditions

  • Leukemia
  • Lymphoma

Interventions

  • asparaginaseDrug

  • cyclophosphamideDrug

  • cytarabineDrug

  • daunorubicin hydrochlorideDrug

  • dexamethasoneDrug

  • doxorubicin hydrochlorideDrug

  • etoposideDrug

  • leucovorin calciumDrug

  • mercaptopurineDrug

  • methotrexateDrug

  • methylprednisoloneDrug

  • mitoxantrone hydrochlorideDrug

  • prednisoloneDrug

  • therapeutic hydrocortisoneDrug

  • thioguanineDrug

  • vincristine sulfateDrug

  • vindesineDrug

  • allogeneic bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival after first randomization
  2. Disease-free survival after second and third randomization

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Ziekenhuis Netwerk Antwerpen Middelheim

    Antwerp, Belgium

  • Hopital Universitaire Des Enfants Reine Fabiola

    Brussels, Belgium

  • Academisch Ziekenhuis der Vrije Universiteit Brussel

    Brussels, Belgium

  • Ghent University

    Ghent, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • U.Z. Gasthuisberg

    Leuven, Belgium

  • Centre Hospitalier Regional de la Citadelle

    Liège, Belgium

  • Clinique de l'Esperance

    Montegnée, Belgium

  • Centre Hospitalier Regional et Universitaire d'Angers

    Angers, France

  • CHR de Besancon - Hopital Saint-Jacques

    Besançon, France

  • CHU de Caen

    Caen, France

  • CHU de Grenoble - Hopital de la Tronche

    Grenoble, France

  • Hopital Debrousse

    Lyon, France

  • Hopital Arnaud de Villeneuve

    Montpellier, France

  • CHR Hotel Dieu

    Nantes, France

  • Hopital de l'Archet CHU de Nice

    Nice, France

  • CHU - Hopital Robert Debre

    Paris, France

  • Hopital Jean Bernard

    Poitiers, France

  • Hopital Americain

    Reims, France

  • Hopital Universitaire Hautepierre

    Strasbourg, France

  • Hopital des Enfants

    Toulouse, France

  • Hospital Escolar San Joao

    Porto, Portugal

  • Instituto Portugues de Oncologia Centro do Porto, SA

    Porto, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.